Live Breaking News & Updates on உலகளவில் ஆராய்ச்சி

Stay updated with breaking news from உலகளவில் ஆராய்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pfizer Vaccine Protection Wanes After 6 Months Study Finds


Pfizer Vaccine Protection Wanes After 6 Months Study Finds
July 28, 2021 – Pfizer’s COVID-19 vaccine continues to show strong protection against serious illness and hospitalization after 6 months, but overall protection against the virus appears to wane after a half a year, according to a new study.
The July 28, 2021, pre-print report of the study, which has not been peer-reviewed, suggests a gradual declining trend in vaccine efficacy over 6 months after two doses of the Pfizer vaccine in more than 45,000 people worldwide.
The study finds overall effectiveness falls from 96% to 84%.
At the same time, a third booster dose of the Pfizer vaccine increases neutralizing antibody levels against the Delta variant by more than 5 times, compared to levels after just a second dose in people ages 18 to 55 years old, new data from Pfizer shows. ....

United States , Mikael Dolsten , Worldwide Research , National Institutes Of Health , World Health Organization , National Institutes , ஒன்றுபட்டது மாநிலங்களில் , உலகளவில் ஆராய்ச்சி , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , தேசிய நிறுவனங்கள் ,

Pfizer (PFE) Q2 2021 Earnings Call Transcript


Operator
Good day, everyone, and welcome to Pfizer s second-quarter 2021 earnings conference call. Today s call is being recorded. At this time, I would like to turn the call over to Mr. Chris Stevo, senior vice president and chief investment relations officer.
Please go ahead, sir.
Senior Vice President and Chief Investment Relations Officer
Thank you, Sylvia. Good morning. It s my pleasure to be welcoming you to Pfizer s second-quarter earnings call for the first time as the head of investor relations at Pfizer. I m joined today by Dr.
Albert Bourla, our chairman and CEO; Frank D Amelio, our CFO; Mikael Dolsten, president of worldwide research and development and medical; Angela Hwang, group president, Pfizer Biopharmaceuticals Group; John Young, our chief business officer; and Doug Lankler, general counsel. We ll begin the call with remarks by Albert, followed by a pipeline update from Mikael, and Frank will then give you his thoughts on the numbers and our ....

United States , Boston University , United Kingdom , Frank Damelio , Daniel Busby , Andrew Baum , Albert Bourla , Kerry Holford Berenberg , Chris Stevo , Carter Gould , Angela Hwang , Doug Lankler , Andrew Baum Citi , Kerry Holford , Geoff Meacham , Carter Gould Barclays , America Merrill Lynch , Matthew Harrison Morgan Stanley , Mikael Dolsten , Chris Schott , Matthew Harrison , Geoffrey Porges , John Young , Ronny Gal , Morgan Stanley , Boston Medical Center ,